Phase I Study of GSK233705 in Healthy Japanese Male Subjects

Pulmonary Disease, Chronic Obstructive Clinical Trial

Official title:

Phase I Study of GSK233705- A Randomised, Double Blind, Placebo-controlled, 2-parts Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Inhaled Doses of GSK233705 From a Novel Dry Powder Device in Healthy Japanese Male Subjects -

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00964405
• Other study ID #: 112016
• Status: Completed
• Phase: Phase 1
• First received: August 13, 2009
• Last updated: August 1, 2017
• Start date: September 20, 2008
• Est. completion date: December 20, 2008

Study information

• Verified date: August 2017
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomised, double blind, placebo-controlled, 2-parts study to investigate the safety, tolerability, and pharmacokinetics of single and repeat inhaled doses of GSK233705 from a novel dry powder device in healthy Japanese male subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 28
• Est. completion date: December 20, 2008
• Est. primary completion date: December 20, 2008
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 20 Years to 64 Years

Eligibility

Inclusion Criteria:

1. Japanese healthy male subjects aged between 20 and 64 years of age inclusive. Healthy subjects are defined as individuals who are free from clinically significant illness or disease as determined by their medical history, physical examination, laboratory studies, and other tests.

2. Body weight = 50kg and BMI within the range 18.50-25.00kg/m2 inclusive.

3. Non-smokers (never smoked or not smoking for >6 months with <10 pack years history (Pack years = (cigarettes per day smoked/20) x number of years smoked))

4. Normal spirometry (FEV1 = 80% of predicted, FEV1/FVC = 70%).

5. Clinical laboratory tests data obtained at screening meet the following:

AST(GOT), ALT(GPT), total-bilirubin: below the upper limit of the normal ranges

6. Normal 12-lead EGC finding at screening; QTc interval <450msec

7. A mean blood pressure lower than 140/90mmHg at screening.

8. Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

9. Capable of using the novel dry powder inhaler.

Exclusion Criteria:

1. The subject has any clinically relevant abnormality on medical examination, vital sign, clinical laboratory test or medical history at screening in the medical opinion of the investigator or the subject has a medical history that is not considered as eligible for inclusion in this study by the investigator.

2. The subject is currently participating in another clinical study or post-marketing study in which the subject is or will be exposed to an investigational or a non-investigational drug or device.

3. The subject has participated in a clinical study with an investigational or a non-investigational drug or device during the previous 4 months.

4. A history of breathing problems (i.e. history of asthmatic symptomatology, asthma in childhood).

5. The subject has a known allergy or hypersensitivity to ipratropium bromide, tiotropium, atropine and any of its derivatives.

6. The subject has a known allergy or hypersensitivity to milk protein or the excipients lactose monohydrate and magnesium stearate.

7. The subject has a history or current conditions of drug abuse or alcoholism.

8. History of regular alcohol consumption exceeding on average, 14 drinks/week (1 drink=5 ounces (150mL) of wine or 350mL of beer or 1.5 ounces (45mL) of 80 proof distilled spirits) within 6 month of screening.

9. The subject is positive for urine drug screening.

10. The subject is positive for syphilis, HBs antigen, HCV antibody, HIV antibody, HTLV-1 antibody.

11. The subject has donated a unit of blood ">400mL" within the previous 4 months or ">200mL" within the previous 1 month.

Related Conditions & MeSH terms

• Chronic Disease
• Lung Diseases
• Pulmonary Disease, Chronic Obstructive

Intervention

Drug:
• GSK233705
Inhaled Long acting muscarinic receptor antagonist
• Placebo
Matching placebo

Locations

Country	Name	City	State
Japan	GSK Investigational Site	Fukuoka

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

Japan, 

References & Publications (1)

This study has not been published in the scientific literature.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety:adverse events, vital sign, ECGs, and clinical laboratory test
Primary	PK:Cmax, tmax and AUC(0-t)

External Links

•   Results for study 112016 can be found on the GSK Clinical Study Register.